Spring 2019 Course:


  • Meg Krench (TA)
  • Jessica Sagers (TA)
  • Rebecca Fine (TA)
  • Will Orent (TA)
  • Ariel (Wei Hsi) Yeh
  • Abir Yamak
  • Yusuf Erkul
  • Anika Gupta
  • Anthony Zlaket
  • Brett Geiger
  • Christy Kuo
  • David Migl
  • David Thompson
  • Elaine Oberlick
  • Emeka Okoro
  • Hugo Caicedo
  • Ida Pavlichenko
  • Iris Braunstein
  • Jamie Zhan
  • Kevin Huang
  • Lena Afeyan
  • Michael Mazzola
  • Norah Owiti
  • Rachel Schecter
  • Soufiane Aboulhouda
  • Tanya Yatsunenko
  • Suan Tuang
  • Xiaobo Ke

Spring 2019 Curriculum


  • “This course is the ‘Freakonomics’ of the biotech industry

    – a unique insider’s perspective on investing, how common conventions create misaligned incentives, and how investors and executives can buck tradition to create better outcomes for all stakeholders. I highly recommend the course to anyone in the biotech ecosystem.”

    – David Migl

  • “The course has debunked many myths for me, and motivated me to one day consider my future in the biotech space!”

    – Hugo Caicedo

  • “A must-take class for anyone interested in the biotech sector! Worth every second of your time.”

    – Norah Owiti

  • “You will view the biotech ecosystem in a completely different way and wonder how these brilliant/controversial ideas are never discussed in schools.”

    – Kevin Huang

  • “Guided by Dr. Kolchinsky and a remarkable peer group,

    the class urges individuals to conceptualize their tremendous roles, responsibilities and potential in this rapidly evolving field. The class explores business, financial and regulatory innovation that is actively evolving to support scientific advances. If you are interested in the ecosystem that transforms scientific innovation into commercial reality, consider this course!”

    – Iris Braunstein

  • “Beyond learning the jargon of biotech financing,

    students who take this course will conceive how biotech executives can incentivize investors and scientists to align with their missions, how drug prices are determined and justified, and how understanding the competitive landscape can inform successful commercialization. Peter Kolchinsky and his team provide unparalleled access to materials and support necessary to delve deeply into these important questions that are necessary to bridge bench to bedside. I recommend this course without any hesitation.”

    – Michael Mazzola

  • “They say what they’ll do, and they’ll do what they say.

    Through data-driven insights, seminal case studies, and Peter’s deep memory bank, this short but intensive course provides a framework for understanding complex and fundamental topics in biotech. You won’t get this educational experience anywhere else.”

    – Soufiane Aboulhouda

  • “You won’t be given numbers or terms to memorize,

    you will witness how the business fundamentals work, how to approach biotech decisions based on available data, how to identify and disintegrate bad ideas, and how to build and leverage an analytical framework that can adequately explain past outcomes and accurately predict future scenarios.”

    – Yusuf Erkul

  • “This course provided me with a solution-oriented framework

    with which to think about the science I pursue–one that grounds my explorations in principles of value creation for the healthcare industry and the patients it serves.”

    – Anika Gupta

Who is this for and why should you take this course?

So much of what’s important to success in the biotechnology sector is not as it seems – we have watched many people (including ourselves) learn difficult lessons through trial and error. This seems inefficient and possibly unnecessary. We believe that by exposing people with the potential to be this industry’s future leaders to advanced concept they might otherwise only learn later in their careers, they will better navigate the biotechnology industry and more quickly achieve their potential.

Our goal is to focus on concepts that are not yet taught in other courses in biotechnology. For example, drug pricing influences R&D yet is widely misunderstood, biotech business models that seem more stable can actually make a company more risky for both to employees and investors than business models that may appear less stable; and entrepreneurs often struggle to reconcile the straightforward economic promises of the business plans they are pitching with the obscure behavioral economics that govern how investors often make decisions.

We can probably all remember a single course, a single lecture, or even a single book that fundamentally changed our thinking and repeatedly guides our decisions. That’s the kind of course we have designed: a short, intense upgrade for people planning on a career in or related to biotechnology, whether in companies, as investors, as lawyers, academic founders, or government.

No prior knowledge of business is necessary, though an advanced background in the life sciences and/or healthcare is required, and therefore this course is limited to people who are currently in or recently graduated (within 2 years) from biomedical and related graduate programs or medical school or who majored in biology in college (graduated within last 4 years) and have work experience in biotech. Business and law school students may apply if they have a strong background in biomedical sciences. Not for current undergraduates.

Click below to learn about upcoming courses offered from RA Capital


If you have questions, contact Jessica Sagers at jsagers@racap.com